Diabetes, Vol 42, Issue 12 1694-1699, Copyright © 1993 by American Diabetes Association

ARTICLES

Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production in NIDDM

I Puhakainen and H Yki-Jarvinen
Second Department of Medicine, University of Helsinki, Finland.

We determined whether overnight inhibition of lipolysis by a long-acting nicotinic acid derivative (acipimox) decreases gluconeogenesis from lactate in NIDDM patients. For this purpose, 250 mg of acipimox or placebo was administered in a double-blind crossover study at 2400, 0400, and 0800 to 8 NIDDM patients (54 +/- 4 yr of age, body mass index 29.5 +/- 1.3 kg/m2, fasting plasma glucose 11 +/- 1 mM). The next morning, total hepatic glucose production (glucose Ra) and gluconeogenesis from lactate were determined using primed, continuous infusions of [3-3H]glucose and [U-14C]acetate. Glucose and lipid oxidation rates were measured using indirect calorimetry. Mean overnight serum free fatty acid concentrations averaged 242 +/- 8 microM after acipimox and 721 +/- 30 microM after placebo (P < 0.001). Inhibition of lipolysis decreased lipid oxidation from 33 +/- 3 to 22 +/- 2 J.kg-1 x min-1 (P < 0.001) and increased carbohydrate oxidation from 15 +/- 3 to 23 +/- 2 mumol.kg-1.min-1 (P < 0.005). Gluconeogenesis from lactate decreased by approximately 40%, from 6.2 +/- 0.6 to 3.8 +/- 0.5 mumol.kg-1 x min-1 (P < 0.005); lactate oxidation increased from 5.6 +/- 0.8 to 7.9 +/- 1.1 mumol.kg-1 x min-1 (P < 0.005), with no change in plasma lactate concentrations or total lactate Rd. Fasting plasma glucose concentrations were comparable at 2400 (10.0 +/- 1.1 vs. 10.6 +/- 1.3 mM, acipimox vs. placebo) and between 0900 and 1000 (10.6 +/- 1.3 and 11.3 +/- 1.3 mM, respectively). Also, total glucose production rates remained unchanged (14.0 +/- 1.2 vs. 14.9 +/- 1.3 mol.kg-1 x min-1, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Everett-Grueter, D. S. Edgerton, E. P. Donahue, S. Vaughan, C. A. Chu, D. K. Sindelar, and A. D. Cherrington The effect of an acute elevation of NEFA concentrations on glucagon-stimulated hepatic glucose output Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E449 - E459. [Abstract] [Full Text] [PDF]

				B. J. Lamont, S. Visinoni, B. C. Fam, M. Kebede, B. Weinrich, S. Papapostolou, H. Massinet, J. Proietto, J. Favaloro, and S. Andrikopoulos Expression of Human Fructose-1,6-Bisphosphatase in the Liver of Transgenic Mice Results in Increased Glycerol Gluconeogenesis Endocrinology, June 1, 2006; 147(6): 2764 - 2772. [Abstract] [Full Text] [PDF]

				H. van Thien, G. J. Weverling, M. T. Ackermans, N. canh Hung, E. Endert, P. A. Kager, and H. P. Sauerwein FFAs are not involved in regulation of gluconeogenesis and glycogenolysis in adults with uncomplicated P. falciparum malaria Am J Physiol Endocrinol Metab, October 1, 2004; 287(4): E609 - E615. [Abstract] [Full Text] [PDF]

				A. Gastaldelli, Y. Miyazaki, M. Pettiti, E. Buzzigoli, S. Mahankali, E. Ferrannini, and R. A. DeFronzo Separate Contribution of Diabetes, Total Fat Mass, and Fat Topography to Glucose Production, Gluconeogenesis, and Glycogenolysis J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3914 - 3921. [Abstract] [Full Text] [PDF]

				H. Bays, L. Mandarino, and R. A. DeFronzo Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478. [Full Text] [PDF]

				S. M. Gustavson, C. A. Chu, M. Nishizawa, B. Farmer, D. Neal, Y. Yang, S. Vaughan, E. P. Donahue, P. Flakoll, and A. D. Cherrington Glucagon's actions are modified by the combination of epinephrine and gluconeogenic precursor infusion Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E534 - E544. [Abstract] [Full Text] [PDF]

				S. M. Gustavson, C. A. Chu, M. Nishizawa, B. Farmer, D. Neal, Y. Yang, E. P. Donahue, P. Flakoll, and A. D. Cherrington Interaction of glucagon and epinephrine in the control of hepatic glucose production in the conscious dog Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E695 - E707. [Abstract] [Full Text] [PDF]

				D. S. Edgerton, S. Cardin, C. Pan, D. Neal, B. Farmer, M. Converse, and A. D. Cherrington. Effects of Insulin Deficiency or Excess on Hepatic Gluconeogenic Flux During Glycogenolytic Inhibition in the Conscious Dog Diabetes, November 1, 2002; 51(11): 3151 - 3162. [Abstract] [Full Text] [PDF]

				P. Singhal, A. Caumo, P. E. Carey, C. Cobelli, and R. Taylor Regulation of endogenous glucose production after a mixed meal in type 2 diabetes Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E275 - E283. [Abstract] [Full Text] [PDF]

				S. Nielsen, N. Moller, S. B. Pedersen, J. S. Christiansen, and J. O. L. Jorgensen The Effect of Long-Term Pharmacological Antilipolysis on Substrate Metabolism in Growth Hormone (GH)-Substituted GH-Deficient Adults J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3274 - 3278. [Abstract] [Full Text] [PDF]

				M. Hawkins, I. Gabriely, R. Wozniak, K. Reddy, L. Rossetti, and H. Shamoon Glycemic Control Determines Hepatic and Peripheral Glucose Effectiveness in Type 2 Diabetic Subjects Diabetes, July 1, 2002; 51(7): 2179 - 2189. [Abstract] [Full Text] [PDF]

				G. F. Lewis, A. Carpentier, K. Adeli, and A. Giacca Disordered Fat Storage and Mobilization in the Pathogenesis of Insulin Resistance and Type 2 Diabetes Endocr. Rev., April 1, 2002; 23(2): 201 - 229. [Abstract] [Full Text] [PDF]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				S. D. Mittelman and R. N. Bergman Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin Am J Physiol Endocrinol Metab, September 1, 2000; 279(3): E630 - E637. [Abstract] [Full Text] [PDF]

				D. A. Podolin, Y. Wei, and M. J. Pagliassotti Effects of a high-fat diet and voluntary wheel running on gluconeogenesis and lipolysis in rats J Appl Physiol, April 1, 1999; 86(4): 1374 - 1380. [Abstract] [Full Text] [PDF]

				N. Danièle, J.-C. Bordet, and G. Mithieux Unsaturated Fatty Acids Associated with Glycogen May Inhibit Glucose-6 Phosphatase in Rat Liver J. Nutr., December 1, 1997; 127(12): 2289 - 2292. [Abstract] [Full Text]

				S. Wise, M. Nielsen, and R. Rizza Effects of Hepatic Glycogen Content on Hepatic Insulin Action in Humans: Alteration in the Relative Contributions of Glycogenolysis and Gluconeogenesis to Endogenous Glucose Production J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1828 - 1833. [Abstract] [Full Text] [PDF]

				F. Fery, L. Plat, M. Baleriaux, and E. O. Balasse Inhibition of Lipolysis Stimulates Whole Body Glucose Production and Disposal in Normal Postabsorptive Subjects J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 825 - 830. [Abstract] [Full Text] [PDF]

				C. A. Chu, S. M. Sherck, K. Igawa, D. K. Sindelar, D. W. Neal, M. Emshwiller, and A. D. Cherrington Effects of free fatty acids on hepatic glycogenolysis and gluconeogenesis in conscious dogs Am J Physiol Endocrinol Metab, February 1, 2002; 282(2): E402 - E411. [Abstract] [Full Text] [PDF]